Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Commun (Camb) ; 52(24): 4549-52, 2016 Mar 25.
Article in English | MEDLINE | ID: mdl-26940541

ABSTRACT

A popular strategy to control cellular growth and differentiation is the employment of self-assembling peptides as biomaterials. In this study we decorated ultrashort helical N-acetylated ß-tripeptides with cell adhesion signals IKVAV and RGD, which spontaneously self-assemble to give nanofibres with multiple signals, and form a bioscaffold that supports the growth of cells.


Subject(s)
Cell Adhesion , Oligopeptides/chemistry , Microscopy, Atomic Force , Microscopy, Electron, Transmission , Protein Folding , Tissue Scaffolds
2.
Diab Vasc Dis Res ; 13(1): 56-68, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26408644

ABSTRACT

BACKGROUND: Glucagon-like peptide-1 receptor agonists may have a role in modulation of cardiac fibrosis. Our study aimed to determine the effect of the glucagon-like peptide-1 receptor agonist liraglutide in obesity, hypertension and age-induced murine models of cardiac fibrosis and identify associated molecular mechanisms. METHODS: C57Bl/6J mice on a high-fat diet and C57Bl/6J mice on a normal chow diet treated with angiotensin II were used to induce obesity and hypertension-mediated cardiac fibrosis, respectively. C57Bl/6J mice 20 months old were used to study age-induced cardiac fibrosis. Liraglutide treatment of 30 µg/kg/day-300 µg/kg s.c. twice daily was administered for 4 weeks. RESULTS: Liraglutide treatment attenuated obesity, hypertension and age-induced increases in interstitial cardiac fibrosis and expression of inflammatory and oxidative stress markers. CONCLUSIONS: These observations identify a potential role for liraglutide in the prevention of cardiac fibrosis and identify molecular mechanisms associated with these effects.


Subject(s)
Aging/drug effects , Glucagon-Like Peptide-1 Receptor/agonists , Heart Diseases/pathology , Heart/drug effects , Incretins/pharmacology , Liraglutide/pharmacology , Myocardium/pathology , Oxidative Stress/drug effects , Angiotensin II/pharmacology , Animals , Aorta/drug effects , Blood Pressure/drug effects , Body Weight/drug effects , Chemokine CCL2/drug effects , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Diet, High-Fat , Disease Models, Animal , Endothelium, Vascular/drug effects , Fibrosis , Heart Diseases/metabolism , Hypertension/chemically induced , Hypertension/metabolism , I-kappa B Proteins/drug effects , I-kappa B Proteins/metabolism , Immunohistochemistry , Inflammation , Interleukin-10/genetics , Macrophages/drug effects , Male , Mice , Mice, Inbred C57BL , Myocardium/metabolism , NF-kappa B p50 Subunit/drug effects , NF-kappa B p50 Subunit/genetics , Obesity/metabolism , Real-Time Polymerase Chain Reaction , Vasoconstrictor Agents/pharmacology , Vimentin/drug effects , Vimentin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...